Sapient is an end-to-end biomarker discovery partner for pharmaceutical and biotechnology sponsors, providing solutions from large-scale untargeted discovery screening of small molecule biomarkers through development of targeted, quantitative CLIA assays to support drug programs at every phase. Our platform combines next-gen rapid liquid chromatography-mass spectrometry (rLC-MS) technologies – able to assay >11,000 small molecule biomarkers per biosample – computational learning, and an expansive proprietary Human Biology Database with data from several hundred thousand biosamples. Together these approaches enable discovery of circulating biomarkers at unprecedented speed and scale, and rapidly deliver actionable insights that align patients, disease biology, and specific therapies. Sapient's platform reduces the time and complexity of biomarker discovery and validation, and drives greater understanding of biological processes, disease progression, and drug responsiveness to optimize drug pipelines for success and accelerate clinical development.